# Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

> **NCT04933968** · PHASE1,PHASE2 · TERMINATED · sponsor: **AlloVir** · enrollment: 17 (actual)

## Conditions studied

- Respiratory Tract Viral Infections
- Human Metapneumovirus (hMPV) Infection
- Parainfluenza (PIV) Infection
- Respiratory Syncytial Viral (RSV) Infection
- Influenza Infection

## Interventions

- **BIOLOGICAL:** ALVR106
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04933968
- **Lead sponsor:** AlloVir
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-21
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Strategic sponsor decision
- **Last updated:** 2024-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04933968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04933968, "Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT04933968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*